Neural Regeneration Research ›› 2025, Vol. 20 ›› Issue (3): 794-796.doi: 10.4103/NRR.NRR-D-23-02106
Previous Articles Next Articles
Neville Ng*, #, Michelle Newbery#, Nicole Miles, Lezanne Ooi*
Online:
Published:
Contact:
Supported by:
Abstract: Mitochondrial dysfunction and neurodegeneration: Progressive neurodegenerative diseases affect a significant proportion of the population; in a single year, there are as many as 276 million disabilities and 9 million deaths as a result of neurological diseases. Mitochondrial function, aging, and neurodegenerative processes appear to be intricately linked; central nervous system degeneration is a major feature of loss-of-function mitochondrial diseases, involving mutation of nuclear or mitochondrial DNA. Meanwhile, mitochondrial dysfunction occurs during healthy aging and is further associated with several neurological diseases, including Alzheimer’s disease (AD), Huntington’s disease, Friedreich’s ataxia, multiple sclerosis, motor neuron disease, Parkinson’s disease (PD), and vanishing white matter disease (VWMD) (Figure 1A). Aging increases neurodegenerative risk factors and processes, including progressively impaired cognitive and/or motor function due to cellular dysfunction, senescence, and/or neuronal death. Furthermore, impaired mitochondrial respiration, biogenesis, mitophagy, and axonal transport can be causative factors in dysfunctional protein synthesis, folding, aggregation, and trafficking, as well as inflammation, oxidative stress, and genomic instability.
Neville Ng, Michelle Newbery, Nicole Miles, Lezanne Ooi. Mitochondrial therapeutics and mitochondrial transfer for neurodegenerative diseases and aging[J]. Neural Regeneration Research, 2025, 20(3): 794-796.
0 / / Recommend
Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks
URL: https://www.sjzsyj.com.cn/EN/10.4103/NRR.NRR-D-23-02106
https://www.sjzsyj.com.cn/EN/Y2025/V20/I3/794